Shenzhen Lifotronic Technology Co (688389) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Shenzhen Lifotronic Technology Co (688389) has a cash flow conversion efficiency ratio of 0.025x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥53.10 Million ≈ $7.77 Million USD) by net assets (CN¥2.10 Billion ≈ $306.77 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Shenzhen Lifotronic Technology Co defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Shenzhen Lifotronic Technology Co - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Shenzhen Lifotronic Technology Co's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Shenzhen Lifotronic Technology Co Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Shenzhen Lifotronic Technology Co ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AGF Management Limited
F:A3J
|
-0.021x |
|
Invesco Municipal Opportunity Trust
NYSE:VMO
|
0.021x |
|
China Chippacking Technology Co. Ltd. A
SHG:688216
|
N/A |
|
Hubeiyichang Transportation Group Co Ltd
SHE:002627
|
0.023x |
|
Zhongyin Babi Food Co. Ltd.
SHG:605338
|
0.102x |
|
COMPASS PATHW SP.ADR
F:5Y6
|
0.715x |
|
Raydium Semi-Conductor
TW:3592
|
-0.003x |
|
Bintulu Port Holdings Bhd
KLSE:5032
|
0.060x |
Annual Cash Flow Conversion Efficiency for Shenzhen Lifotronic Technology Co (2016–2025)
The table below shows the annual cash flow conversion efficiency of Shenzhen Lifotronic Technology Co from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see Shenzhen Lifotronic Technology Co (688389) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥2.11 Billion ≈ $308.57 Million |
CN¥280.97 Million ≈ $41.11 Million |
0.133x | -7.90% |
| 2024-12-31 | CN¥2.05 Billion ≈ $299.89 Million |
CN¥296.47 Million ≈ $43.38 Million |
0.145x | -14.41% |
| 2023-12-31 | CN¥1.80 Billion ≈ $263.05 Million |
CN¥303.82 Million ≈ $44.46 Million |
0.169x | -10.21% |
| 2022-12-31 | CN¥1.44 Billion ≈ $211.23 Million |
CN¥271.71 Million ≈ $39.76 Million |
0.188x | +30.06% |
| 2021-12-31 | CN¥1.26 Billion ≈ $184.08 Million |
CN¥182.07 Million ≈ $26.64 Million |
0.145x | +21.33% |
| 2020-12-31 | CN¥1.14 Billion ≈ $167.34 Million |
CN¥136.42 Million ≈ $19.96 Million |
0.119x | +36.36% |
| 2019-12-31 | CN¥1.05 Billion ≈ $153.60 Million |
CN¥91.82 Million ≈ $13.44 Million |
0.087x | -27.94% |
| 2018-12-31 | CN¥668.39 Million ≈ $97.81 Million |
CN¥81.14 Million ≈ $11.87 Million |
0.121x | +102.24% |
| 2017-12-31 | CN¥587.25 Million ≈ $85.93 Million |
CN¥35.25 Million ≈ $5.16 Million |
0.060x | -20.50% |
| 2016-12-31 | CN¥370.82 Million ≈ $54.26 Million |
CN¥28.00 Million ≈ $4.10 Million |
0.076x | -- |
About Shenzhen Lifotronic Technology Co
Shenzhen Lifotronic Technology Co., Ltd. research, develops, manufactures, and markets medical devices for diagnostics, therapy, clinical medicine, skin, and human health related purposes in China. The company offers IVD products, such as HPLC, ECLIA, and hematology system; rapid test, molecular and POCT diagnostics. It also offers therapeutic products comprising respiratory and ICU, and wound ca… Read more